Impel Pharmaceuticals Inc.

Impel NeuroPharma, Inc. , based in the US, is a biotechnology company focused on developing innovative intranasal drug delivery solutions for treating neurological conditions such as migraines. Founded in 2008 in Seattle, US, Impel NeuroPharma is dedicated to revolutionizing drug delivery through its proprietary technology. The company has engaged in 19 deals and most recently secured a GRANT of USD 500,000 from the National Institute of Mental Health, raising a total of USD 45.

00 mn. Impel Pharmaceuticals specializes in innovative intranasal drug delivery solutions, notably its flagship product, Trudhesa® (dihydroergotamine mesylate) nasal spray, which is approved for the acute treatment of migraines in adults. Utilizing Precision Olfactory Delivery (POD®) technology, Trudhesa® enhances drug absorption via the upper nasal space, promising rapid and consistent bioavailability. This technology not only addresses acute migraine management but also holds potential for expansion into additional therapeutic areas, catering to both healthcare providers and patients with unmet medical needs across North America and Europe.

In the most recent fiscal year of 2022, Impel Pharmaceuticals reported a revenue of USD 12. 65 mn and an EBITDA of USD -81. 17 mn, primarily driven by the sales of Trudhesa® to healthcare providers such as hospitals and specialty clinics focused on migraine treatment. Impel NeuroPharma plans to utilize the recent GRANT funding of USD 500,000 to support the development of new products and enhance its market presence.

The company aims to expand its geographic reach, particularly targeting additional European markets by the end of 2024, while continuing to innovate within the intranasal drug delivery sector.